Literature DB >> 34027049

Relevance of aneuploidy for cancer therapies targeting the spindle assembly checkpoint and KIF18A.

Yael Cohen-Sharir1, Uri Ben-David1.   

Abstract

Aneuploidy, a common feature of cancer cells, results in increased sensitivity to the inhibition of the spindle assembly checkpoint (SAC) and the mitotic motor protein Kinesin Family Member 18A (KIF18A). We discuss the importance of drugs targeting SAC core members and KIF18A. We stress the need to assess the sensitivity to this class of drugs at appropriate time points, and propose that aneuploidy could serve as a biomarker to stratify patients for SAC-targeting treatments.
© 2021 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Aneuploidy; KIF18A; SAC; cancer; cancer therapies; spindle assembly checkpoint

Year:  2021        PMID： 34027049      PMCID： PMC8128200          DOI： 10.1080/23723556.2021.1915075

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Genomic and Functional Approaches to Understanding Cancer Aneuploidy.

Authors:  Alison M Taylor; Juliann Shih; Gavin Ha; Galen F Gao; Xiaoyang Zhang; Ashton C Berger; Steven E Schumacher; Chen Wang; Hai Hu; Jianfang Liu; Alexander J Lazar; Andrew D Cherniack; Rameen Beroukhim; Matthew Meyerson
Journal:  Cancer Cell       Date:  2018-04-02       Impact factor: 31.743

2.  Loss of Kif18A Results in Spindle Assembly Checkpoint Activation at Microtubule-Attached Kinetochores.

Authors:  Louise M E Janssen; Tessa V Averink; Vincent A Blomen; Thijn R Brummelkamp; René H Medema; Jonne A Raaijmakers
Journal:  Curr Biol       Date:  2018-08-16       Impact factor: 10.834

Review 3.  Causes and consequences of aneuploidy in cancer.

Authors:  David J Gordon; Benjamin Resio; David Pellman
Journal:  Nat Rev Genet       Date:  2012-01-24       Impact factor: 53.242

Review 4.  Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.

Authors:  Shutao Wang; Muxin Zhang; Di Liang; Wei Sun; Chaozai Zhang; Mengnan Jiang; Junli Liu; Jiaguo Li; Chenchen Li; Xiaohong Yang; Xiaoping Zhou
Journal:  Eur J Med Chem       Date:  2019-04-20       Impact factor: 6.514

Review 5.  Context is everything: aneuploidy in cancer.

Authors:  Uri Ben-David; Angelika Amon
Journal:  Nat Rev Genet       Date:  2019-09-23       Impact factor: 53.242

Review 6.  Cellular Stress Associated with Aneuploidy.

Authors:  Jin Zhu; Hung-Ji Tsai; Molly R Gordon; Rong Li
Journal:  Dev Cell       Date:  2018-02-26       Impact factor: 12.270

7.  Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition.

Authors:  Yael Cohen-Sharir; James M McFarland; Mai Abdusamad; Carolyn Marquis; Sara V Bernhard; Mariya Kazachkova; Helen Tang; Marica R Ippolito; Kathrin Laue; Johanna Zerbib; Heidi L H Malaby; Andrew Jones; Lisa-Marie Stautmeister; Irena Bockaj; René Wardenaar; Nicholas Lyons; Ankur Nagaraja; Adam J Bass; Diana C J Spierings; Floris Foijer; Rameen Beroukhim; Stefano Santaguida; Todd R Golub; Jason Stumpff; Zuzana Storchová; Uri Ben-David
Journal:  Nature       Date:  2021-01-27       Impact factor: 69.504

8.  Whole-genome doubling confers unique genetic vulnerabilities on tumour cells.

Authors:  Ryan J Quinton; Amanda DiDomizio; Marc A Vittoria; Kristýna Kotýnková; Carlos J Ticas; Sheena Patel; Yusuke Koga; Jasmine Vakhshoorzadeh; Nicole Hermance; Taruho S Kuroda; Neha Parulekar; Alison M Taylor; Amity L Manning; Joshua D Campbell; Neil J Ganem
Journal:  Nature       Date:  2021-01-27       Impact factor: 69.504

Review 9.  The diverse consequences of aneuploidy.

Authors:  Narendra Kumar Chunduri; Zuzana Storchová
Journal:  Nat Cell Biol       Date:  2019-01-02       Impact factor: 28.824

10.  Chromosomally unstable tumor cells specifically require KIF18A for proliferation.

Authors:  Carolyn Marquis; Cindy L Fonseca; Katelyn A Queen; Lisa Wood; Sarah E Vandal; Heidi L H Malaby; Joseph E Clayton; Jason Stumpff
Journal:  Nat Commun       Date:  2021-02-22       Impact factor: 14.919
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.